Exhibit 13

Meridian Bioscience, Inc. and Subsidiaries

Selected Financial Data
(Amounts in thousands, except for per share data)

Income Statement Information

		FY 2009				FY 2008				FY 2007				FY 2006				FY 2005
Net sales		$	148,274			$	139,639			$	122,963			$	108,413			$	92,965
Gross profit			92,783				86,480				74,940				64,684				54,890
Operating income			48,779				44,350				35,030				26,894				20,325
Net earnings			32,759				30,202				26,721				18,333				12,638
Basic earnings per share		$	0.81			$	0.75			$	0.67			$	0.47			$	0.36
Diluted earnings per share		$	0.80			$	0.74			$	0.66			$	0.46			$	0.35
Cash dividends declared per share		$	0.65			$	0.53			$	0.40			$	0.28			$	0.21
Book value per share		$	3.40			$	3.19			$	2.83			$	2.40			$	2.14

Balance Sheet Information

		FY 2009				FY 2008				FY 2007				FY 2006				FY 2005
Current assets		$	117,147			$	99,458			$	93,745			$	80,742			$	69,725
Current liabilities			16,752				16,061				17,067				20,617				19,791
Total assets			155,997				146,431				132,698				120,528				110,134
Long-term debt obligations			—				—				—				1,803				2,684
Shareholders’ equity			137,905				128,489				112,948				94,350				83,333

FORWARD LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can also change expected results. One of Meridian’s main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian’s operations. The Company cannot predict the possible effects of potential healthcare reform in the United States and similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.

CORPORATE PROFILE

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

MERIDIAN BIOSCIENCE, INC. 1

Meridian Bioscience, Inc. and Subsidiaries

Corporate Data

Corporate Headquarters
3471 River Hills Drive
Cincinnati, Ohio 45244
(513) 271-3700

Legal Counsel
Keating Muething & Klekamp PLL
Cincinnati, Ohio

Independent Public Accountants
Grant Thornton LLP
Cincinnati, Ohio

Transfer Agent, Registrar and Dividend Reinvestment Administration

Shareholders requiring a change of name, address or ownership of stock, as well as information about shareholder records, lost or stolen certificates, dividend checks, dividend direct deposit, and dividend reinvestment should contact: Computershare Investor Services LLC, P. O. Box 43078, Providence, RI 02940-3078; (888) 294-8217 or (312) 601-4332: e-mail web.queries@computershare.com; or submit your inquiries online through www.computershare.com/contactus.

Annual Meeting

The annual meeting of the shareholders will be held on Thursday, January 21, 2010 at 2:00 p.m. Eastern Time at the Holiday Inn Eastgate, 4501 Eastgate Boulevard, Cincinnati, OH 45245.

Directions to the Holiday Inn Eastgate can be found on our website: www.meridianbioscience.com.

Common Stock Information

NASDAQ Global Select Market Symbol: “VIVO.” Approximate number of beneficial holders: 22,000. Approximate number of record holders: 950.

The following table sets forth by calendar quarter the high and low sales prices of the Common Stock on the NASDAQ Global Select Market.

Years Ended September 30,		2009								2008
Quarter ended:		High				Low				High				Low
December 31			30.250				19.430				34.240				26.500
March 31			26.410				16.500				36.090				28.910
June 30			23.000				14.790				37.000				25.200
September 30			26.200				20.750				30.500				23.250

Directors and Officers

Directors				Officers and Executives
William J. Motto Executive Chairman of the Board John A. Kraeutler Chief Executive Officer James A. Buzard, Ph.D. Retired Executive Vice President, Merrell Dow Pharmaceuticals, Inc. Gary P. Kreider Senior Partner, Keating Muething & Klekamp PLL		Robert J. Ready Chairman of the Board and President, LSI Industries Inc. David C. Phillips Co-founder, Cincinnati Works, Inc. James M. Anderson President and Chief Operating Officer, Cincinnati Children’s Hospital Medical Center		William J. Motto Executive Chairman of the Board John A. Kraeutler Chief Executive Officer Richard L. Eberly Executive Vice President, President Meridian Life Science Lawrence J. Baldini Executive Vice President, Operations and Information Systems Melissa A. Lueke Executive Vice President, Chief Financial Officer and Secretary		Antonio A. Interno Senior Vice President, President and Managing Director, Meridian Bioscience Europe Susan D. Rolih Senior Vice President, Regulatory Affairs and Quality Assurance Todd W. Motto Vice President, Sales and Marketing Vecheslav A. Elagin Vice President, Research and Development Marviette Dale Vice President, Human Resources

PERFORMANCE GRAPH

The following graph shows the yearly percentage change in Meridian’s cumulative total shareholder return on its Common Stock as measured by dividing the sum of (A) the cumulative amount of dividends, assuming dividend reinvestment during the periods presented and (B) the difference between Meridian’s share price at the end and the beginning of the periods presented; by the share price at the beginning of the periods presented with the Wilshire 5000 Equity Index and a Peer Group Index. The Old Peer Group consists of Biomerica, Inc., Idexx Laboratories Corp., Inverness Medical Innovations, Neogen Corp., Orasure Technologies Inc., Quidel Corp., Strategic Diagnostics Inc. and Trinity Biotech Plc. The New Peer Group Consists of Biomerica, Inc., Idexx Laboratories Corp., Inverness Medical Innovations, Life Technologies Corp., Neogen Corp., Orasure Technologies Inc., Quidel Corp., Strategic Diagnostics Inc. and Trinity Biotech Plc. The Old Peer Group is different from the New Peer Group because of a merger made by one of Meridian’s peers during fiscal 2009.